Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

We studied the relation between adherence to imatinib measured with microelectronic monitoring systems and the probabilities of losing a complete cytogenetic response (CCyR) and of imatinib failure in 87 CCyR chronic myeloid leukemia patients receiving long-term therapy. We included in our analysis...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2011-04, Vol.117 (14), p.3733-3736
Hauptverfasser:	Ibrahim, Amr R., Eliasson, Lina, Apperley, Jane F., Milojkovic, Dragana, Bua, Marco, Szydlo, Richard, Mahon, Francois-Xavier, Kozlowski, Kasia, Paliompeis, Christos, Foroni, Letizia, Khorashad, Jamshid S., Bazeos, Alex, Molimard, Mathieu, Reid, Alistair, Rezvani, Katayoun, Gerrard, Gareth, Goldman, John, Marin, David
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Benzamides Biological and medical sciences Brief Report Chromosome Aberrations - drug effects Chromosome Aberrations - statistics & numerical data Clinical Trials and Observations Disease-Free Survival Drug Resistance, Neoplasm Female Follow-Up Studies Hematologic and hematopoietic diseases Humans Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Middle Aged Myeloid Neoplasia Patient Compliance - statistics & numerical data Piperazines - therapeutic use Pyrimidines - therapeutic use Remission Induction Time Factors Treatment Failure
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!